Plain-English translation of NCT06576973 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adbelimumab—a newer immunotherapy medication—works better when combined with chemotherapy and a targeted drug called apatinib to shrink esophageal cancer before surgery. All participants will receive this three-drug combination for 4 treatment cycles before having surgery to remove the cancer, followed by possible radiation therapy based on their individual situation.
Esophageal cancer is a serious disease, and surgery alone doesn't always prevent the cancer from coming back. This medication combination may help shrink tumors more effectively before surgery and reduce the chance of recurrence after surgery.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital for 4 cycles of treatment with the three-drug combination, spaced over several weeks. About 4–6 weeks after your last dose, you will have surgery to remove the cancer. After surgery, you may receive radiation therapy depending on your situation. You may also continue to receive adbelimumab for up to one year after surgery. Throughout the study, you will be monitored regularly until the cancer progresses, you choose to withdraw, or the study ends.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China